Orphan Drugs in Asia-Pacific
From designation to pricing, funding & market access
| Feb 2010 |
£1,450 |
Kuwait Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
African Pharmaceutical Directory
2010
| Jan 2010 |
£94 |
Lithuania Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
Slovakia Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
Oman Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
Snapshots UK Pharmaceuticals 2009
| Jan 2010 |
£300 |
Morocco Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
South Africa Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
The Turkish Pharmaceutical Market Outlook to 2014
Policy Environment, Market Structure, Competitive Landscape, Growth Opportunities
| Jan 2010 |
£2,405 |
Spain Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
Belarus Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
United Kingdom Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
Snapshots Austria Pharmaceuticals 2009
| Jan 2010 |
£300 |
The Japanese Pharmaceutical Market Outlook to 2014
Policy environment, market structure, competitive landscape, growth opportunities
| Jan 2010 |
£2,405 |
India Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
Chile Pharmaceuticals and Healthcare Report Q1 2010
| Jan 2010 |
£250 |
Business Strategy: Health Insights Country Report for China
| Dec 2009 |
£2,820 |
France Pharmaceuticals and Healthcare Report Q1 2010
| Dec 2009 |
£250 |
Singapore Pharmaceuticals and Healthcare Report Q1 2010
| Dec 2009 |
£250 |
Germany Defence and Security Report Q1 2010
| Dec 2009 |
£250 |
Indian Pharmaceuticals Industry Report
| Dec 2009 |
£600 |
The US Pharmaceutical Market 2009-2024
| Nov 2009 |
£1,499 |
Estonia Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Russia Infrastructure Report Q1 2010
| Nov 2009 |
£250 |
Germany Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Bulgaria Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Moldova Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Philippines Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Slovenia Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Latvia Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Netherlands Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Indonesia Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
South Korea Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Bangladesh Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Hungary Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Taiwan Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Italy Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Pakistan Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Indian Pharmaceutical Market Outlook 2009-2024
| Nov 2009 |
£1,499 |
Turkey Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Nigeria Infrastructure Report Q1 2010
| Nov 2009 |
£250 |
Egypt Infrastructure Report Q1 2010
| Nov 2009 |
£250 |
Argentina Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Algeria Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Belgium Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Mexico Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Iran Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Asia Pacific Pharma Sector Analysis
| Nov 2009 |
£755 |
Thailand Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Uzbekistan Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Australia Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Poland Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
Croatia Pharmaceuticals and Healthcare Report Q1 2010
| Nov 2009 |
£250 |
China Pharma Outsourcing Annual Review
2009
| Nov 2009 |
£870 |
Snapshots Bulgaria Pharmaceuticals 2009
| Oct 2009 |
£300 |
United Kingdom Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
China Pharmaceutical Chain Industry Report
2009
| Oct 2009 |
£1,065 |
India Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
Russia Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
China Healthcare Sector Analysis
| Oct 2009 |
£755 |
Peru Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
Snapshots France Pharmaceuticals 2009
| Oct 2009 |
£300 |
Spain Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
Snapshots Australia Pharmaceuticals 2009
| Oct 2009 |
£300 |
United States Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
Estonia Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
Czech Republic Pharmaceuticals and Healthcare Report Q4 2009
| Oct 2009 |
£250 |
CHINA: Major report covers impact of health reforms on China's Pharmaceutical Market
Impact of China's Health Reforms
| Oct 2009 |
£120 |
The Pharmaceutical Market: Denmark
| Sep 2009 |
£595 |
The Pharmaceutical Market: Norway
| Sep 2009 |
£595 |
The Pharmaceutical Market: France
| Sep 2009 |
£595 |
The Pharmaceutical Market: Slovenia
Opportunities and Challenges
| Sep 2009 |
£595 |
The Pharmaceutical Market: Hungary
| Sep 2009 |
£595 |
The Pharmaceutical Market: Ireland
Opportunities and Challenges
| Sep 2009 |
£595 |
The Pharmaceutical Market: Bangladesh
Opportunities and Challenges
| Sep 2009 |
£595 |
The Pharmaceutical Market: Spain
Opportunities and Challenges
| Sep 2009 |
£595 |
Thailand Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Japan Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Ukraine Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Belgium Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Iran Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Greece Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Singapore Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Moldova Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Chile Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Romania Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Israel Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Italy Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Kuwait Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Taiwan Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Germany Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Netherlands Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
The Pharmaceutical Market: Israel
| Sep 2009 |
£595 |
Colombia Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
The Pharmaceutical Market: New Zealand
| Sep 2009 |
£595 |
Kazakhstan Pharmaceuticals and Healthcare Report
Q4 2009
| Sep 2009 |
£250 |
Qatar Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Vietnam Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
Brazil Pharmaceuticals and Healthcare Report Q4 2009
| Sep 2009 |
£250 |
